AIMS: Toll-like receptor ( @entity14540 ligand CpG-oligodeoxynucleotide ( @entity58004 ) exerts preconditioning in @entity741 /reperfusion. We hypothesized a postconditioning effect of @entity58004 in a @entity19 closed-chest model of @entity583 . MATERIALS AND METHODS: C57BL/6 (12weeks, male, @entity7097 ) @entity19 were instrumented at the left anterior descending artery, then allowed 5d of recovery before 30min @entity63 . Treatments comprised: 1) PBS: 250 l @entity1391 buffer solution intraperitoneally 5min before reperfusion and 2) IPC (ischemic postconditioning): 3 twenty-second reperfusion and occlusion episodes at the end of @entity63 3) @entity58004 : 1668 thioate 0.2 mol/kg BW intraperitoneally 5min before reperfusion. @entity1188 size was assessed via @entity5045 (TTC) staining after 2 and 24h reperfusion. Myocardial mRNA-expression of cytokines was measured using real-time PCR after 2h reperfusion. @entity4357 -3 kinase (PI3K)-inhibitor @entity2307 was injected intraperitoneally in @entity7097 15min before postconditioning and PBS in each group. Cardiac function in @entity7097 was assessed with a left-ventricular pressure-volume catheter at 24h reperfusion. KEY FINDINGS: Following 30min @entity63 and 2h reperfusion, @entity1188 size was diminished by 90% in @entity7097 postconditioned with @entity58004 (2.4  1.55 IS/AAR%) and IPC (1.98  1.03 IS/AAR%) compared to PBS @entity19 (23.2  3.97 IS/AAR%). @entity1188 size increased following 24h reperfusion but the differences remained robust. Expression of @entity637 and @entity1618 was increased in @entity58004 . @entity2307 abolished the postconditioning effect of @entity58004 and IPC. Ejection fraction and preload-recruitable @entity64 work were significantly greater in @entity58004 @entity19 . SIGNIFICANCE: @entity58004 confers postconditioning via activation of @entity14540 . Cardiac function is preserved following @entity58004 postconditioning. The PI3K -inhibitor @entity2307 attenuates @entity58004 postconditioning.

Postconditioning with a CpG containing Oligodeoxynucleotide ameliorates XXXX in a @entity19 closed-chest model.

@entity5045 :: ('MESH:C009591', 'Chemical') :: ['triphenyltetrazolium chloride'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity7097 :: ('MESH:C536751', 'Disease') :: ['WT'] @entity58004 :: ('MESH:C408982', 'Chemical') :: ['CpG-ODN'] @entity2307 :: ('MESH:C009687', 'Chemical') :: ['wortmannin', 'Wortmannin'] @entity1618 :: ('16153(Tax:10090)', 'Gene') :: ['IL-10'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['Infarct', 'infarct'] @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity637 :: ('21926(Tax:10090)', 'Gene') :: ['TNF-a'] @entity14540 :: ('81897(Tax:10090)', 'Gene') :: ['TLR9', 'TLR)9'] @entity4357 :: ('MESH:D010716', 'Chemical') :: ['Phosphatidylinositol']
@entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']
